Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Budhi Singh Yadav, Treshita Dey
Locoregional radiotherapy play an important role in controlling the disease after surgery in patients with breast cancer. Radiotherapy schedules vary from conventional fraction to hypofractionation. The purpose of this review is to get an insight into the data on regional nodal irradiation (RNI) with hypofractionation in patients with breast cancer. This systematic review was constructed in accordance with Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) framework. Electronic databases such as PubMed, Cochrane and EMBASE were searched from January 1, 2023 to March 31, 2023 to identify studies published in English language on hypofractionated RNI in post mastectomy patients...
March 14, 2024: Clinical Breast Cancer
#22
JOURNAL ARTICLE
E Giuliani Meredith, Edith Filion, Sergio Faria, Vijayananda Kundapur, Toni Vu Thi Trinh Thuc, Benjamin H Lok, Srinivas Raman, Houda Bahig, Joanna M Laba, Pencilla Lang, Alexander V Louie, Andrew Hope, George B Rodrigues, Andrea Bezjak, Marie-Pierre Campeau, Marie Duclos, Scott Bratman, Anand Swaminath, Rohan Salunkhe, Andrew Warner, David A Palma
INTRODUCTION: The use of stereotactic body radiotherapy (SBRT) for tumors in close proximity to the central mediastinal structures has been associated with a high risk of toxicity. This study (BLINDED FOR REVIEW) aimed to determine the maximally tolerated dose (MTD) of SBRT for ultra-central (UC) non-small cell lung carcinoma (NSCLC), using a time-to-event continual reassessment methodology (TITE-CRM). METHODS: Patients with T1-3N0M0 (≤ 6 cm) NSCLC were eligible...
April 11, 2024: International Journal of Radiation Oncology, Biology, Physics
#23
JOURNAL ARTICLE
Joseph Lombardo, Edward Castillo, Richard Castillo, Ryan Miller, Bernard Jones, Moyed Miften, Brian Kavanagh, Adam Dicker, Cullen Boyle, Benjamin Leiby, Joshua Banks, Nicole L Simone, Benjamin Movsas, Inga Grills, Thomas Guerrero, Chad G Rusthoven, Yevgeniy Vinogradskiy
PURPOSE: A novel form of lung function imaging has been developed that uses 4DCT data to generate lung ventilation images (4DCT-ventilation). Functional avoidance uses 4DCT-ventilation to reduce doses to functional lung with the aim of reducing pulmonary side-effects. A 4DCT-ventilation functional avoidance, phase II, multi-center clinical trial was completed. The purpose of this work is to quantify patient reported outcomes (PRO) changes for patients treated with functional avoidance and to determine which metrics are predictive of PRO changes...
April 11, 2024: International Journal of Radiation Oncology, Biology, Physics
#24
JOURNAL ARTICLE
Charles A Kunos, Molly E Martin, Michalis F Georgiou, Russ A Kuker, Aman Chauhan
Radiation oncologists, radiopharmacists, nuclear medicine physicians, and medical oncologists have seen a renewed clinical interest in radiopharmaceuticals for the curative or the palliative treatment of cancer. To allow for the discovery and the clinical advancement of targeted radiopharmaceuticals, these stakeholders have reformed their trial efforts and remodeled their facilities to accommodate the obligations of a program centered upon radioactive investigational drug products. Now considered informally as drugs and not beam radiotherapy, radiopharmaceuticals can be more easily studied in the traditional clinical trial enterprise ranging from phase 0-I to phase III studies...
April 2, 2024: Cancers
#25
REVIEW
Anke M J Kuijpers, Alexander C J van Akkooi
Melanoma treatment is leading the neo-adjuvant systemic (NAS) therapy field. It is hypothesized that having the entire tumor in situ, with all of the heterogeneous tumor antigens, allows the patient's immune system to have a broader response to the tumor in all its shapes and forms. This translates into a higher clinical efficacy. Another benefit of NAS therapy potentially includes identifying patients who have a favorable response, which could offer an opportunity for the de-escalation of the extent of surgery and the need for adjuvant radiotherapy and/or adjuvant systemic therapy, as well as tailoring the follow-up in terms of the frequency of visits and cross-sectional imaging...
March 22, 2024: Cancers
#26
JOURNAL ARTICLE
Clémence Basse, Jonathan Khalifa, François Thillays, Cécile Le Pechoux, Jean-Michel Maury, Pierre-Emmanuel Bonte, Alexandre Coutte, Nicolas Pourel, Vincent Bourbonne, Olivier Pradier, Aurélie Belliere, Florence Le Tinier, Mélanie Deberne, Ronan Tanguy, Fabrice Denis, Laetitia Padovani, Audrey Zaccariotto, Thierry Molina, Lara Chalabreysse, Geoffrey Brioude, Bertrand Delatour, Jean-Christophe Faivre, Kim Cao, Philippe Giraud, François-Georges Riet, Sébastien Thureau, Delphine Antoni, Carole Massabeau, Audrey Keller, Emilie Bonnet, Delphine Lerouge, Etienne Martin, Nicolas Girard, Angela Botticella
BACKGROUND: Thymomas are rare intrathoracic malignancies that can relapse after surgery. Whether or not Post-Operative Radiotherapy (PORT) should be delivered after surgery remains a major issue. RADIORYTHMIC is an ongoing, multicenter, randomized phase 3 trial addressing this question in patients with completely R0 resected Masaoka-Koga stage IIb/III thymoma. Experts in the field met to develop recommendations for PORT. METHODS: A scientific committee from the RYTHMIC network identified key issues regarding the modalities of PORT in completely resected thymoma...
April 10, 2024: Journal of Thoracic Oncology
#27
REVIEW
Qun-Li Ren, Xiao-Lan Li, Tian Tian, Shuang Li, Rong-Yi Shi, Qian Wang, Yuan Zhu, Miao Wang, Huan Hu, Jian-Guo Liu
Oral squamous cell carcinoma (OSCC) is the most common malignant cancer of the head and neck, with high morbidity and mortality, ranking as the sixth most common cancer in the world. The treatment of OSCC is mainly radiotherapy, chemotherapy and surgery, however, the prognosis of patients is still poor and the recurrence rate is high. This paper reviews the range of effects of natural medicinal plant active ingredients (NMPAIs) on OSCC cancer, including the types of NMPAIs, anti-cancer mechanisms, involved signaling pathways, and clinical trials...
April 12, 2024: Chinese Journal of Integrative Medicine
#28
JOURNAL ARTICLE
Voraporn Yongprayoon, Napasporn Wattanakul, Winnada Khomate, Nathakrit Apithanangsiri, Tarathip Kasitipradit, Danupon Nantajit, Mahvash Tavassoli
As a member of BET (bromodomain and extra-terminal) protein family, BRD4 (bromodomain‑containing protein 4) is a chromatin‑associated protein that interacts with acetylated histones and actively recruits regulatory proteins, leading to the modulation of gene expression and chromatin remodeling. The cellular and epigenetic functions of BRD4 implicate normal development, fibrosis and inflammation. BRD4 has been suggested as a potential therapeutic target as it is often overexpressed and plays a critical role in regulating gene expression programs that drive tumor cell proliferation, survival, migration and drug resistance...
June 2024: Oncology Reports
#29
JOURNAL ARTICLE
Sarah El-Nakeep, Samragnyi Madala, Anusha Chidharla, Balarama Krishna Surapaneni, Subhrajit Saha, Benjamin Martin, Anup Kasi
BACKGROUND: Radical excision (RE) for rectal cancer carries a higher risk of mortality and morbidity, while local excision (LE) could decrease these postoperative risks. However, the long-term benefit of LE is still debatable. AIM: To study the effectiveness of LE versus RE in T1 and T2 rectal cancer. METHODS: A systematic review and meta-analysis was conducted using key databases like PubMed and ClinicalTrials.gov. Only cohort studies and randomized controlled trials were included...
2024: Arch Intern Med Res
#30
REVIEW
Elena Palassini, Giacomo Giulio Baldi, Sara Sulfaro, Marta Barisella, Giuseppe Bianchi, Domenico Campanacci, Marco Fiore, Marco Gambarotti, Massimiliano Gennaro, Carlo Morosi, Federico Navarria, Emanuela Palmerini, Claudia Sangalli, Marta Sbaraglia, Annalisa Trama, Sebastian Asaftei, Giuseppe Badalamenti, Rossella Bertulli, Alexia Francesca Bertuzzi, Roberto Biagini, Angela Bonadonna, Antonella Brunello, Dario Callegaro, Ferdinando Cananzi, Marco Cianchetti, Paola Collini, Danila Comandini, Annalisa Curcio, Lorenzo D'Ambrosio, Tommaso De Pas, Angelo Paolo Dei Tos, Virginia Ferraresi, Andrea Ferrari, Alessandro Franchi, Anna Maria Frezza, Elena Fumagalli, Matteo Ghilli, Daniela Greto, Giovanni Grignani, Michele Guida, Toni Ibrahim, Marco Krengli, Roberto Luksch, Andrea Marrari, Marinella Mastore, Alessandra Merlini, Giuseppe Maria Milano, Piera Navarria, Maria Abbondanza Pantaleo, Antonina Parafioriti, Ilaria Pellegrini, Elisabetta Pennacchioli, Marco Rastrelli, Elisabetta Setola, Salvatore Tafuto, Salvatore Turano, Sergio Valeri, Bruno Vincenzi, Viviana Vitolo, Andrei Ivanescu, Fiammetta Paloschi, Paolo Giovanni Casali, Alessandro Gronchi, Silvia Stacchiotti
Angiosarcoma (AS) represents a rare and aggressive vascular sarcoma, posing distinct challenges in clinical management compared to other sarcomas. While the current European Society of Medical Oncology (ESMO) clinical practice guidelines for sarcoma treatment are applicable to AS, its unique aggressiveness and diverse tumor presentations necessitate dedicated and detailed clinical recommendations, which are currently lacking. Notably, considerations regarding surgical extent, radiation therapy (RT), and neoadjuvant/adjuvant chemotherapy vary significantly in localized disease, depending on each different site of onset...
March 30, 2024: Cancer Treatment Reviews
#31
JOURNAL ARTICLE
John R de Almeida, Rosemary Martino, Ali Hosni, David P Goldstein, Scott V Bratman, Douglas B Chepeha, John N Waldron, Ilan Weinreb, Bayardo Perez-Ordonez, Eugene Yu, Ur Metser, Aaron R Hansen, Wei Xu, Susie Jie Su, John Kim
IMPORTANCE: Patients with unknown primary squamous cell carcinoma (CUP) with cervical metastases typically receive comprehensive radiotherapy (RT) of the pharynx and bilateral neck. Typically, these patients receive comprehensive RT of the pharynx and bilateral neck that may produce treatment-related toxic effects. OBJECTIVE: To determine whether localization of occult oropharyngeal cancers with transoral robotic surgery (TORS) combined with reduced pharyngeal and neck RT volumes provides acceptable disease control...
April 11, 2024: JAMA Otolaryngology—Head & Neck Surgery
#32
JOURNAL ARTICLE
Nicholas P Verdini, Karolina L Bryl, Raymond E Baser, Kaitlyn Lapen, Jun J Mao, Erin F Gillespie
IMPORTANCE: Clinical trials are critical for progress in oncology; however, only 5% of the adult cancer population participates. Harnessing data that are routinely collected (ie, electronic patient-reported outcomes [ePROs]) may serve as a method to promote trial enrollment. OBJECTIVE: To evaluate if an ePRO-prompted recruitment strategy is associated with increased clinical trial enrollment. DESIGN, SETTING, AND PARTICIPANTS: A randomized substudy was conducted from September 2022 to March 2023 at a multisite tertiary cancer center as part of an ongoing clinical trial that was testing a symptom-intervention for cancer-related fatigue...
April 11, 2024: JAMA Oncology
#33
JOURNAL ARTICLE
George Rodrigues, Kristin A Higgins, Andreas Rimner, Arya Amini, Joe Y Chang, Stephen G Chun, Jessica Donington, Martin J Edelman, Matthew A Gubens, Puneeth Iyengar, Benjamin Movsas, Matthew S Ning, Henry S Park, Andrea Wolf, Charles B Simone
IMPORTANCE: The treatment of locally advanced non-small cell lung cancer (LA-NSCLC) has been informed by more than 5 decades of clinical trials and other relevant literature. However, controversies remain regarding the application of various radiation and systemic therapies in commonly encountered clinical scenarios. OBJECTIVE: To develop case-referenced consensus and evidence-based guidelines to inform clinical practice in unresectable LA-NSCLC. EVIDENCE REVIEW: The American Radium Society (ARS) Appropriate Use Criteria (AUC) Thoracic Committee guideline is an evidence-based consensus document assessing various clinical scenarios associated with LA-NSCLC...
April 11, 2024: JAMA Oncology
#34
Guilherme Vilhais, Diogo Alpuim Costa, Mário Fontes-Sousa, Pedro Casal Ribeiro, Filipa Martinho, Carolina Botelho de Sousa, Catarina Rodrigues Santos, Ida Negreiros, Ana Canastra, Paula Borralho, Ana Guia Pereira, Cristina Marçal, José Germano Sousa, Renata Chaleira, Júlio César Rocha, Conceição Calhau, Ana Faria
Locally advanced breast cancer poses significant challenges to the multidisciplinary team, in particular with hormone receptor (HR) positive, HER2-negative tumors that classically yield lower pathological complete responses with chemotherapy. The increasingly significant use of CDK 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) in different breast cancer settings has led to clinical trials focusing on this strategy as a primary treatment, with promising results. The impact of the microbiota on cancer, and vice-versa, is an emerging topic in oncology...
2024: Frontiers in Oncology
#35
JOURNAL ARTICLE
H L Gong, S Tian, H Ding, L Tao, L Wang, J Wang, T Wang, M Zhang, Y Shi, C Z Xu, C P Wu, S Z Wang, L Zhou
Objective: To evaluate the objective response rate (ORR) of induction chemoimmunotherapy with camrelizumab plus TPF (docetaxel, cisplatin, and capecitabine) for locally advanced hypopharyngeal squamous cell carcinoma (LA HSCC) and potential predictive factors for ORR. Methods: A single-center, prospective, phase 2 and single-arm trial was conducted for evaluating antitumor activity of camrelizumab+TPF(docetaxel+cisplatin+capecitabine) for LA HSCC between May 21, 2021 and April 15, 2023, patients admitted to the Eye & ENT Hospital affiliated with Fudan University...
April 8, 2024: Zhonghua Er Bi Yan Hou Tou Jing Wai Ke za Zhi, Chinese Journal of Otorhinolaryngology Head and Neck Surgery
#36
JOURNAL ARTICLE
Tracy T Batchelor, Sharmila Giri, Amy S Ruppert, Susan Geyer, Scott E Smith, Nimish Mohile, Lode J Swinnen, Jonathan W Friedberg, Brad S Kahl, Nancy L Bartlett, Eric D Hsi, Bruce David Cheson, Nina D Wagner-Johnston, Lakshmi Nayak, John P Leonard, James Louis Rubenstein
While it is evident that standard dose whole brain radiotherapy as consolidation is associated with significant neurotoxicity, the optimal consolidative strategy for primary central nervous system lymphoma (PCNSL) is not defined. We performed a randomized phase 2 clinical trial via the U.S. Alliance cancer cooperative group to compare myeloablative consolidation supported by autologous stem cell transplantation with non-myeloablative consolidation after induction therapy for PCNSL. This is the first randomized trial to be initiated that eliminates whole brain radiotherapy as a consolidative approach in newly-diagnosed PCNSL...
April 10, 2024: Blood Advances
#37
MULTICENTER STUDY
Jana de Boniface, Tove Filtenborg Tvedskov, Lisa Rydén, Robert Szulkin, Toralf Reimer, Thorsten Kühn, Michalis Kontos, Oreste D Gentilini, Roger Olofsson Bagge, Malin Sund, Dan Lundstedt, Matilda Appelgren, Johan Ahlgren, Sophie Norenstedt, Fuat Celebioglu, Helena Sackey, Inge Scheel Andersen, Ute Hoyer, Per F Nyman, Eva Vikhe Patil, Elinore Wieslander, Henrik Dahl Nissen, Sara Alkner, Yvette Andersson, Birgitte V Offersen, Leif Bergkvist, Jan Frisell, Peer Christiansen
BACKGROUND: Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited statistical power, uncertain nodal radiotherapy target volumes, and a scarcity of data on relevant clinical subgroups. METHODS: We conducted a noninferiority trial in which patients with clinically node-negative primary T1 to T3 breast cancer (tumor size, T1, ≤20 mm; T2, 21 to 50 mm; and T3, >50 mm in the largest dimension) with one or two sentinel-node macrometastases (metastasis size, >2 mm in the largest dimension) were randomly assigned in a 1:1 ratio to completion axillary-lymph-node dissection or its omission (sentinel-node biopsy only)...
April 4, 2024: New England Journal of Medicine
#38
REVIEW
Lauren Schaff, Lakshmi Nayak, Christian Grommes
The incidence of primary central nervous system lymphoma (PCNSL) has steadily increased, particularly in elderly patients. Although highly responsive to first-line chemotherapy and radiotherapy, approximately 50% of patients relapse or become refractory within 1 year. Prognosis following relapse is dismal and no standard salvage therapy exists. Bruton's tyrosine kinase (BTK), a key regulator of the B-cell receptor (BCR) pathway, has emerged as a promising therapeutic target. The first BTK inhibitor ibrutinib has been evaluated in the relapsed/refractory PCNSL setting, with overall response rates of 51...
April 10, 2024: Leukemia & Lymphoma
#39
REVIEW
Nina Mogensen, Carmen Cananau, Susanna Ranta, Jonas Karlén, Anna Kwiecinska, Fredrik Baecklund
AIM: To describe a rare case of primary refractory Hodgkin lymphoma nodular sclerosis syncytial variant in a child and review immunotherapy in relapsed/refractory Hodgkin lymphoma. METHODS: We described the treatment course of a child with primary refractory classic Hodgkin lymphoma and discussed different options for salvage therapy, with an emphasis on immunotherapy. We searched PubMed for all published clinical trials investigating immunotherapy in classic Hodgkin lymphoma written in English until 31 June, 2023...
April 10, 2024: Acta Paediatrica
#40
JOURNAL ARTICLE
Morten Horsholt Kristensen, Anne Ivalu Sander Holm, Christian Rønn Hansen, Ruta Zukauskaite, Eva Samsøe, Christian Maare, Jørgen Johansen, Hanne Primdahl, Åse Bratland, Claus Andrup Kristensen, Maria Andersen, Jens Overgaard, Jesper Grau Eriksen
INTRODUCTION: Patients with failure after primary radiotherapy (RT) for head and neck squamous cell carcinoma (HNSCC) have a poor prognosis. This study investigates pattern of failure after primary curatively intended IMRT in a randomized controlled trial in relation to HPV/p16 status. MATERIAL AND METHODS: Patients with HNSCC of the oral cavity, oropharynx (OPSCC), hypopharynx or larynx were treated with primary curative IMRT (+/-cisplatin) and concomitant nimorazole between 2007 and 12...
May 2024: Clinical and Translational Radiation Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
